PsychonautWiki Archive

3-MeO-PCE: Difference between revisions

← Older edit
>Unity
Fixed citation
>Blackhole
added important category
 
(17 intermediate revisions by 10 users not shown)
Line 5: Line 5:
'''3-Methoxyeticyclidine''' (also known as '''Methoxieticyclidine''' and '''3-MeO-PCE''') is a novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class that produces [[dissociative]] and [[hallucinogenic]] effects when [[Routes of administration|administered]]. It is a structural analog of [[PCE]].  
'''3-Methoxyeticyclidine''' (also known as '''Methoxieticyclidine''' and '''3-MeO-PCE''') is a novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class that produces [[dissociative]] and [[hallucinogenic]] effects when [[Routes of administration|administered]]. It is a structural analog of [[PCE]].  


3-MeO-PCE began to gain popularity in 2010 <ref>3-MeO-PCE - Explore - Google Trends | https://www.google.com/trends/explore?date=all&q=3-MeO-PCE</ref> and is sold on the online grey area [[research chemical]] market as a legal alternative to [[PCP]] or [[ketamine]].<ref>Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. | https://www.ncbi.nlm.nih.gov/pubmed/26360516</ref><ref>From the Street to the Laboratory: Analytical Profiles of Methoxetamine, 3-Methoxyeticyclidine and 3-Methoxyphencyclidine and their Determination in Three Biological Matrices
3-MeO-PCE began to gain popularity in 2010 <ref>3-MeO-PCE - Explore - Google Trends | https://www.google.com/trends/explore?date=all&q=3-MeO-PCE</ref> and is sold on the online grey area [[research chemical]] market as a legal alternative to [[PCP]] or [[ketamine]].<ref>{{cite journal | vauthors=((Wallach, J.)), ((Colestock, T.)), ((Cicali, B.)), ((Elliott, S. P.)), ((Kavanagh, P. V.)), ((Adejare, A.)), ((Dempster, N. M.)), ((Brandt, S. D.)) | journal=Drug Testing and Analysis | title=Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines | volume=8 | issue=8 | pages=801–815 | date= August 2016 | issn=1942-7611 | doi=10.1002/dta.1861}}</ref><ref>{{cite journal | vauthors=((De Paoli, G.)), ((Brandt, S. D.)), ((Wallach, J.)), ((Archer, R. P.)), ((Pounder, D. J.)) | journal=Journal of Analytical Toxicology | title=From the Street to the Laboratory: Analytical Profiles of Methoxetamine, 3-Methoxyeticyclidine and 3-Methoxyphencyclidine and their Determination in Three Biological Matrices | volume=37 | issue=5 | pages=277–283 | date=1 June 2013 | url=https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkt023 | issn=0146-4760 | doi=10.1093/jat/bkt023}}</ref><ref>{{Citation | title=nsddb.eu | url=http://nsddb.eu/substance/296/}}</ref>  
| http://jat.oxfordjournals.org/content/37/5/277.full</ref><ref>http://nsddb.eu/substance/296/</ref>  


Very little data exists about the pharmacological properties, metabolism, and toxicity of 3-MeO-PCE, and it has a very brief history of human usage. It is strongly recommended that one use harm reduction practices if using this substance.  
Very little data exists about the pharmacological properties, metabolism, and toxicity of 3-MeO-PCE, and it has a very brief history of human usage. It is strongly recommended that one use harm reduction practices if using this substance.  
Line 17: Line 16:
3-MeO-PCE acts principally as an [[NMDA receptor antagonist]]. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].”
3-MeO-PCE acts principally as an [[NMDA receptor antagonist]]. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].”


3-MeO-PCE has Ki values of 61 nM for the NMDA receptor, 743 nM for the dopamine transporter, 2097 nM for the histamine H2 receptor, 964 nM for the Alpha-2A adrenergic receptor, 115 nM for the serotonin transporter, 4519 nM for the σ1 receptor and 525 nM for the σ2 receptor. <ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref>
3-MeO-PCE has Ki values of 61 nM for the NMDA receptor, 743 nM for the dopamine transporter, 2097 nM for the histamine H2 receptor, 964 nM for the Alpha-2A adrenergic receptor, 115 nM for the serotonin transporter, 4519 nM for the σ1 receptor and 525 nM for the σ2 receptor. <ref>{{cite journal | vauthors=((Roth, B. L.)), ((Gibbons, S.)), ((Arunotayanun, W.)), ((Huang, X.-P.)), ((Setola, V.)), ((Treble, R.)), ((Iversen, L.)) | journal=PLOS ONE | title=Correction: The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | volume=13 | issue=3 | pages=e0194984 | date=22 March 2018 | url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984 | issn=1932-6203 | doi=10.1371/journal.pone.0194984}}</ref>


==Subjective effects==
==Subjective effects==
Line 34: Line 33:
*'''[[Effect::Spontaneous physical sensations]]''' - The  body high of this compound can be described in terms of its style variations as a motionless, constant, sharp, all-encompassing, euphoric general activation of nerve endings across the body. This feels halfway between the same sensations induced by [[3-MeO-PCP]] and [[O-PCE]] and disappears at higher doses due to the disconnecting and anesthetic effects it produces.
*'''[[Effect::Spontaneous physical sensations]]''' - The  body high of this compound can be described in terms of its style variations as a motionless, constant, sharp, all-encompassing, euphoric general activation of nerve endings across the body. This feels halfway between the same sensations induced by [[3-MeO-PCP]] and [[O-PCE]] and disappears at higher doses due to the disconnecting and anesthetic effects it produces.
*'''[[Effect::Physical euphoria]]''' - At lower to moderate dosages, the sensation itself can be described as feelings of physical comfort, warmth and euphoria which spreads throughout the body. However, at heavier dosages, this sensation becomes neutral or potentially uncomfortable in terms of its enjoyability.
*'''[[Effect::Physical euphoria]]''' - At lower to moderate dosages, the sensation itself can be described as feelings of physical comfort, warmth and euphoria which spreads throughout the body. However, at heavier dosages, this sensation becomes neutral or potentially uncomfortable in terms of its enjoyability.
*'''[[Effect::Bodily control enhancement]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards losses in gross and fine. motor control.
*'''[[Effect::Bodily control enhancement]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards losses in gross and fine motor control.
*'''[[Effect::Tactile enhancement]]''' & '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Effect::Tactile enhancement]]''' & '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards losses in gross and fine. motor control.
*'''[[Effect::Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards losses in gross and fine motor control.
*'''[[Effect::Changes in felt gravity]]'''
*'''[[Effect::Changes in felt gravity]]'''
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Appetite suppression]]'''
Line 129: Line 128:
}}
}}
===Experience reports===
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
* [https://erowid.org/experiences/subs/exp_3MEOPCE_.shtml Erowid Experience Vaults: 3-MeO-PCE]
{{#ask: [[Category:3-MeO-PCE]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
 
*[https://erowid.org/experiences/subs/exp_3MEOPCE_.shtml Erowid Experience Vaults: 3-MeO-PCE]


==Toxicity and harm potential==
==Toxicity and harm potential==
{{Further|Research chemicals#Toxicity and harm potential}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational 3-MeO-PCE use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because 3-MeO-PCE has very little history of human usage.  
The toxicity and long-term health effects of recreational 3-MeO-PCE use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because 3-MeO-PCE has very little history of human usage.  


Line 140: Line 142:


It is strongly recommended that one use extreme caution and [[responsible drug use|harm reduction]] practices when using this substance.
It is strongly recommended that one use extreme caution and [[responsible drug use|harm reduction]] practices when using this substance.
*Users should avoid using the substance multiple days in a row or becoming addicted to it as this increases the risk of severe adverse effects.
*The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
*Users should start with extremely low doses and work their way up as slowly as possible. [[Volumetric liquid dosing|Volumetric liquid dosing]] should preferably be used due to the substance's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.<ref>3-MeO-PCE (TripSit) | https://wiki.tripsit.me/wiki/3-MeO-PCE</ref>
*[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose.


Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially [[stimulant]]s, [[psychedelic]]s, or other [[dissociative]]s like [[MXE]]. [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
*Users should avoid using the substance multiple days in a row or becoming addicted to it as this increases the risk of severe adverse effects.
*The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
*Users should start with extremely low doses and work their way up as slowly as possible. [[Volumetric liquid dosing|Volumetric liquid dosing]] should preferably be used due to the substance's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.<ref>3-MeO-PCE (TripSit) | https://wiki.tripsit.me/wiki/3-MeO-PCE</ref>
*[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose.
 
Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially [[stimulants]], [[psychedelics]], or other [[dissociatives]] like [[MXE]]. [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.


It is strongly recommended that one use [[responsible drug use|harm reduction practices]], such as [[volumetric dosing]], when using this substance to ensure the accurate administration of the intended dose.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]], such as [[volumetric dosing]], when using this substance to ensure the accurate administration of the intended dose.


===Tolerance and addiction potential===
===Tolerance and addiction potential===
The chronic use of 3-MeO-PCE can be considered [[Addiction potential::highly addictive with a high potential for adverse side effects such as psychosis]]. In comparison to other [[dissociative]]s, 3-MeO-PCE has been reported to be more habit-forming than [[MXE]], [[diphenidine]], [[ephenidine]], and [[ketamine]]. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.
The chronic use of 3-MeO-PCE can be considered [[Addiction potential::highly addictive with a high potential for adverse side effects such as psychosis]]. In comparison to other [[dissociatives]], 3-MeO-PCE has been reported to be more habit-forming than [[MXE]], [[diphenidine]], [[ephenidine]], and [[ketamine]]. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.


Tolerance to many of the effects of 3-MeO-PCE develops [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). 3-MeO-PCE presents cross-tolerance with [[Cross-tolerance::all [[dissociative]]s]], meaning that after the use of 3-MeO-PCE, all [[dissociative]]s will have a reduced effect.
Tolerance to many of the effects of 3-MeO-PCE develops [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). 3-MeO-PCE presents cross-tolerance with [[Cross-tolerance::all [[dissociatives]]]], meaning that after the use of 3-MeO-PCE, all [[dissociatives]] will have a reduced effect.


===Urinary tract effects===
===Urinary tract effects===
Regarding its long-term health effects when used repeatedly and over excessive periods, 3-MeO-PCE seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is because 3-MeO-PCE is far more potent than ketamine, so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become severe and can be described as:
Regarding its long-term health effects when used repeatedly and over excessive periods, 3-MeO-PCE seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is because 3-MeO-PCE is far more potent than ketamine, so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become severe and can be described as:


*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.  
*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate.
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate.
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
Line 168: Line 171:
===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
*'''[[Psychedelics]]''' - This combination is not advised because 3-MeO-PCE has been reported to cause extreme psychological disturbances such as [[psychosis]] and mania at a significantly higher rate than other [[dissociatives]].
*'''[[Psychedelics]]''' - This combination is not advised because 3-MeO-PCE has been reported to cause extreme psychological disturbances such as [[psychosis]] and mania at a significantly higher rate than other [[dissociatives]].
*'''[[Stimulants]]''' - This combination is not advised because 3-MeO-PCE has been reported to cause extreme psychological disturbances such as [[psychosis]] and mania at a significantly higher rate than other [[dissociatives]].
{{DangerousInteractions/Dissos}}
{{DangerousInteractions/Dissos}}


==Legality==
==Legal status==
{{legalStub}}
{{legalStub}}
*'''United Kingdom''' - 3-MeO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 1-phenylcyclohexylamine substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.<ref>The Misuse of Drugs Act 1971 (Amendment) Order 2013 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2013/239/introduction/made</ref>
 
*'''Czech Republic:'''  6-APB is a Schedule I (List 4) substance. It may be used for research and restricted therapeutic purposes. (§ 1, d), 1. of Nařízení vlády č. 463/2013 Sb.) <ref> https://www.zakonyprolidi.cz/cs/2013-463?text=o+seznamech+n%C3%A1vykov%C3%BDch </ref>
*'''Germany:''' 3-MeO-PCE is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref>
*'''Switzerland:''' 3-MeO-PCE is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' 3-MeO-PCE is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742">{{Citation | title=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü | url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm}}</ref> <ref name="List of illegal substances for law"> https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf</ref>
*'''United Kingdom''' - 3-MeO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 1-phenylcyclohexylamine substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Amendment) Order 2013 | url=https://www.legislation.gov.uk/uksi/2013/239/introduction/made}}</ref>
 
==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
**[[Volumetric dosing]]
**[[Volumetric dosing]]
Line 185: Line 195:


==External links==
==External links==
*[https://en.wikipedia.org/wiki/3-MeO-PCE 3-MeO-PCE (Wikipedia)]
*[https://en.wikipedia.org/wiki/3-MeO-PCE 3-MeO-PCE (Wikipedia)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=966 3-MeO-PCE (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=966 3-MeO-PCE (Isomer Design)]
Line 191: Line 202:


==Literature==
==Literature==
* Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
 
*Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620


==References==
==References==
<references/>
<references />
[[Category:Psychoactive substance]]
 
[[Category:Research chemical]]
[[Category:Psychoactive substance]]a
[[Category:Arylcyclohexylamine]]
[[Category:Arylcyclohexylamine]]
[[Category:Dissociative]]
[[Category:Dissociative]]
[[Category:Psychological dependence]]
[[Category:Research chemical]]


{{#set:Featured=true}}
{{#set:Featured=true}}
Retrieved from "http://psy.st/wiki/3-MeO-PCE"